SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoin is experiencing significant selling pressure, trending as investors react to a hawkish Fed chair pick that is strengthening the dollar and leading to rotation out of riskier assets. This, coupled with notable ETF outflows, has ignited a fierce community debate about whether the market has found a bottom or is facing further declines.

Ethereum is a global, open-source platform for decentralized applications. In other words, it is a decentralized blockchain platform that enables developers to build and deploy smart contracts and applications without central authority control. Unlike Bitcoin, which primarily functions as digital currency, Ethereum operates as a programmable global computer where developers can create any type of decentralized service.   The platform hosts over $14 billion in DeFi applications with hundreds of thousands of active users across financial protocols, NFT marketplaces, and gaming platforms. Its transition to Proof of Stake in September 2022 reduced energy consumption by over 99%, addressing environmental concerns while strengthening network security.  The network operates through thousands of independent validator nodes that process transactions and execute smart contracts on the Ethereum Virtual Machine. Smart contracts are self-executing programs written in Solidity that automatically carry out agreements when conditions are met, eliminating intermediaries like banks or brokers.   Validators stake ETH as collateral to propose and validate blocks, earning rewards for honest participation while facing penalties for malicious behavior. The EIP-1559 upgrade introduced a dynamic base fee mechanism that burns ETH with each transaction, creating deflationary pressure during high network activity when more ETH is burned than issued to validators.  Vitalik Buterin proposed Ethereum in 2013, but seven co-founders helped build it, including Gavin Wood who created Solidity and the EVM technical specification, and Joseph Lubin who founded ConsenSys. The project launched in July 2015 after raising over $18 million through crowdfunding, quickly becoming the largest blockchain developer community. Major milestones include the 2020 Beacon Chain launch, the 2021 London hard fork implementing fee burning, and the 2022 Merge to Proof of Stake.   Ether (ETH) serves multiple functions: paying transaction fees (gas), staking to secure the network and earn 3-5% annual yields, serving as collateral in DeFi protocols, and purchasing NFTs and digital assets. The asset is increasingly adopted by traditional institutions, with publicly traded companies adding ETH to corporate treasuries to generate staking yields while maintaining blockchain exposure, and in 2024, the SEC approved spot Ethereum ETFs, allowing traditional investors to gain exposure through conventional brokerage accounts.  Ethereum's roadmap focuses on dramatically increasing transaction capacity to over 100,000 per second, reducing confirmation times, and enhancing decentralization while maintaining security against future threats like quantum computing.

Ethereum

Ethereum is trending amidst a broad crypto market decline, triggered by President Trump's hawkish Federal Reserve Chair nomination strengthening the dollar, which, combined with widespread liquidations over a low-liquidity weekend, has led to significant price drops. The community is intensely discussing perceived market manipulation and debating whether current levels present a prime "buy the dip" opportunity, with many users critically referencing past bullish price predictions from prominent figures.

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company’s history roots back to the year 1913 when Astra business was formed. AstraZeneca was founded in 1999 through the merger of Astra AB and Zeneca Group PLC. The company is headquartered in Cambridge, the United Kingdom.

Astrazeneca plc - ADR

AstraZeneca PLC

AstraZeneca is trending strongly after delivering a series of positive clinical trial results for its oncology, hypertension, and gastric cancer therapies, concurrently announcing multi-billion dollar investments in China for R&D and obesity drug development with CSPC Pharmaceuticals, and preparing for an NYSE listing to broaden its global investor base. The community is actively discussing the company's robust pipeline and strategic moves positioning it for significant future growth.

VenHub Global, Inc. engages in the management of fully autonomous and robotic-operated convenience stores. It is involved in utilizing technologies such as artificial intelligence (AI) and smart inventory management systems for shopping experience of customers. The company was founded by Shahan Ohanessian and Shoushana Ohanessian on January 31, 2023 and is headquartered in Pasadena, CA.

Venhub Global Inc.

Venhub Global Inc. (VHUB) is trending following its direct listing on NASDAQ, which saw significant after-hours trading volume and a notable price surge, leading to community speculation about its potential as a multi-day runner.

Themes ETF Trust - Leverage Shares 2X Long BBAI Daily ETF

Leverage Shares 2X Long BBAI Daily ETF

$BAIG is trending as a 2x leveraged ETF closely tied to $BBAI, with the community actively discussing its potential for amplified gains and leveraging it for aggressive swing trades or long-term positions amid general bullish sentiment.

Solana is a high-performance Layer 1 blockchain designed for mass adoption by providing a fast, secure, and low-cost environment for decentralized applications. It distinguishes itself by scaling globally without the use of complex sharding or multiple layers, instead maintaining a single, unified ledger to avoid liquidity fragmentation. This architecture allows it to process thousands of transactions per second with sub-second finality, often at a cost of less than a penny per transaction.  The network operates on a unique hybrid model that combines Proof of Stake with an innovation called Proof of History, which functions as a decentralized clock to timestamp transactions. This system reduces the need for constant node communication, allowing the Sealevel engine to run non-conflicting smart contracts in parallel across multiple CPU cores. Further efficiency is gained through the Gulf Stream protocol, which reduces confirmation times by forwarding transactions to validators before the current block is finished.  Founded in 2017 by Anatoly Yakovenko, Solana is now supported by the Switzerland-based Solana Foundation and significant institutional investors like Andreessen Horowitz and Polychain Capital. The platform’s native token, SOL, serves as the primary currency for paying transaction fees, participating in network governance, and securing the system through staking.   Solana has also seen significant institutional adoption ranging from spot Solana ETFs to major partnerships including Visa's 2025 launch of USDC settlement on the network and the tokenization of public equity by firms like Galaxy Digital.

Solana

Solana is sharply down, driving a community divide between those aggressively buying the dip for long-term gains and others predicting further steep declines amid wider crypto market liquidations. Contributing factors include speculation around new Fed leadership and recent discussions regarding a lawsuit impacting its ecosystem, though some highlight continued Solana ETF inflows.

Trump For President

TRUMP CRYPTO is trending due to widespread community discussion surrounding recent political actions by Donald Trump, including his stance on Venezuela and high-profile pardons, which are seen by some as distractions from the Epstein files. The token faces strong polarization, with many critics labeling it a "scam" amid significant price declines, contrasting with supporters who link its value to his ongoing political influence.

Bankr is an advanced AI agent focused on simplifying the process of buying and selling digital assets. Bankr was the first AI agent on Farcaster to help you quickly buy all your favorites coins directly in the social. BankrCoin is the official coin of the agent and was deployed by Bankr itself directly in the Farcaster social feed. Fees from swaps go to support BankrCoin. Bankr is available on Farcaster and will soon be launching a private terminal, token recs, and limit orders on Base.

BankrCoin

BNKR CRYPTO is trending with high volatility and divided community sentiment as it navigates broader crypto market pullbacks. Its association with the "AI Agent tokens on Base" narrative, ongoing ecosystem developments, and strong holder growth are fueling bullish discussions, while others caution about its "pump and dump" nature.

Terra is a decentralized financial payment network that rebuilds the traditional payment stack on the blockchain. Luna is the reserve currency of the Terra platform. It has three core functions: i) mine Terra transactions through staking, ii) ensure the price stability of Terra stablecoins and iii) provide incentives for the platform’s blockchain validators.

Terra Luna Classic

Terra Luna Classic (LUNC) is seeing renewed attention driven by Binance's ongoing burn initiatives, recent public reposts from CZ, and Kraken's reversal of its delisting decision. The community is highly engaged, closely monitoring Do Kwon's sentencing for its potential impact and discussing the project's long-term revival through continued token burns and new ecosystem developments.

Fefe is a memecoin inspired by Matt Furie's book "Mindviscosity," published in 2020.  Follow FEFE, the alter ego of PEPE in the book “Mindviscosity” by Matt Furie.  Fefe is a main character in the book, who is a laid back and carefree frog living in a whimsical world. Fefe's relaxed and adventurous spirit captures the heart of this imaginative universe.  Launched stealth with no presale, zero taxes, LP burnt and contract renounced - TAX: 0/0 This narrative has its roots in a fascinating story.  Join us and become part of the $FEFE community today!

Fefe

FEFE is gaining attention as a community-owned Ethereum memecoin, with supporters emphasizing its unique narrative as the "representation of PEPE" by Matt Furie and its notable resilience in maintaining value and building momentum despite broader market volatility.

statis crypto Watchlist

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>ERNA-101 is designed to activate and regulate the immune system's response to recognize and attack cancer cells.</li><li>The new collaboration comes as the company looks forward to clinical trials for the cell therapy.&nbsp;</li><li>ERNA-101 has shown potential to reprogram immunologically "cold" tumors into "hot" ones, increasing immune cell infiltration and suppressing tumor growth in preclinical studies. &nbsp;</li></ul><blockquote>Shares of Ernexa Therapeutics (ERNA) traded 48% higher on Wednesday afternoon after Cellipont Bioservices announced that it has entered into a collaboration with the company.</blockquote>Cellipont is a cell therapy contract development and manufacturing organization. Its <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.prnewswire.com/news-releases/cellipont-bioservices-and-ernexa-therapeutics-enter-cell-therapy-manufacturing-partnership-to-advance-erna-101-toward-clinical-trials-in-ovarian-cancer-302597673.html">partnership</a> with Ernexa will focus on activities to advance Ernexa’s lead cell therapy called ERNA-101 for the treatment of ovarian cancer into clinical manufacturing and trials.<blockquote>"Cellipont brings deep technical capabilities and a shared sense of urgency to help us translate the promise of ERNA-101 into a clinically viable therapy."&nbsp; -Sanjeev Luther, CEO, Ernexa Therapeutics.</blockquote><h2 class="st-heading-2">About The Cell Therapy</h2>ERNA-101 is designed to activate and regulate the immune system's response to recognize and attack cancer cells. According to Cellipont, it provides a scalable, off-the-shelf treatment, without needing patient-specific cell harvesting, provided it is an allogeneic iMSC therapy using stem cells from a healthy donor rather than the patient themselves.ERNA-101 has shown potential to reprogram immunologically "cold" tumors into "hot" ones, increasing immune cell infiltration and suppressing tumor growth in preclinical studies, the company said. The new collaboration comes as the company looks forward to clinical trials for the cell therapy.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/ERNA">ERNA stock</a> jumped from ‘bearish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘extremely high’ levels.A Stocktwits user expressed optimism for the stock hitting a new high.<stembedurl>https://stocktwits.com/Roza11/message/634186263</stembedurl>Another, however, sees upcoming dilution.<stembedurl>https://stocktwits.com/Tradebub/message/634144629</stembedurl>ERNA stock is down by 58% this year and by 89% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/bridgebio-shares-second-postive-late-stage-study-results-in-a-week-calcium-disorder-drug-trial-yields-positive-results/cLGZvEeR3DT">BridgeBio Shares Second Positive Late-Stage Study Result In A Week – Calcium Disorder Drug Trial Yields Positive Results</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

ERNA Stock Rallies On Collaboration With Contract Manufacturer To Advance Lead Cell Therapy Into Clinical Trials 

The partnership will focus on activities to advance Ernexa’s lead cell therapy called ERNA-101 for the treatment of ovarian cancer into clinical manufacturing and trials. 

Equity

Cellipont Bioservices and Ernexa Therapeutics Enter Cell Therapy Manufacturing Partnership to Advance ERNA-101 Toward Clinical Trials in Ovarian Cancer

Cellipont Bioservices and Ernexa Therapeutics Enter Cell Therapy Manufacturing Partnership to Advance ERNA-101 Toward Clinical Trials in Ovarian Cancer Cellipont Bioservices and Ernexa Therapeutics...

Shares of Ernexa Therapeutics (ERNA) fell 13% on Tuesday morning after the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/06/10/3096816/0/en/Ernexa-Therapeutics-Announces-1-for-15-Reverse-Stock-Split.html">announced</a> a reverse stock split to regain compliance with the $1 minimum bid price required for continued listing on Nasdaq.The reverse stock split will be at a ratio of 1-for-15, effective June 12, 2025, at 12:01 a.m. Eastern Time. The company’s common stock is expected to begin trading on a split-adjusted basis when the market opens on June 12.As a result of the reverse stock split, every 15 shares of the company’s common stock issued and outstanding will be automatically reclassified into one new share of common stock.No fractional shares will be issued in connection with the reverse stock split, and no cash or other consideration will be paid in connection with any fractional shares.As of Tuesday, the company had 110.4 million shares of common stock issued and outstanding, which it anticipates will result in approximately 7.4 million shares of common stock issued and outstanding on a split-adjusted basis.Ernexa also stated that it believes the reverse stock split is a key step in strengthening its financial foundation and maintaining access to the capital markets needed to advance its clinical programs.Ernexa is developing innovative stem cell therapies for the treatment of advanced cancer and autoimmune disease.On Stocktwits, retail sentiment around Ernexa improved from ‘extremely bearish’ to ‘bearish’ territory over the past 24 hours while message volume remained at ‘high’ levels.<figure class="image"><img style="aspect-ratio:629/57;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_10_at_10_35_28_AM_png_969f4ebcc6.webp" alt="ERNA's Sentiment Meter and Message Volume as of 10:30 a.m. ET on June 10, 2025 | Source: Stocktwits" width="629" height="57"><figcaption>ERNA's Sentiment Meter and Message Volume as of 10:30 a.m. ET on June 10, 2025 | Source: Stocktwits</figcaption></figure><a href="https://stocktwits.com/symbol/ERNA">ERNA stock</a> is down by about 56% this year and by about 91% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/tencent-music-expands-audio-empire-with-over-2-billion-ximalaya-merger/chl7VcFRbzk">Tencent Expands Audio Empire With $2.4B Ximalaya Merger: Retail Turns Optimistic</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

Ernexa Stock Drops On 1-For-15 Reverse Stock Split To Regain Nasdaq Compliance: Retail Sentiment Improves But Stays Bearish

As of Tuesday, the company had 110.4 million shares of common stock issued and outstanding, which it anticipates will result in approximately 7.4 million shares on a split-adjusted basis.

This account has been verified as an official ERNA representative.

Verified Account

Ernexa Therapeutics

Ernexa Therapeutics, Inc. engages in the provision of cell engineering therapies. It is involved in the development of mRNA cell engineering technologies to repair cellular dysfunction and treat a range of therapeutic indications. The company was founded in 1984 and is headquartered in Cambridge, MA.

ERNA
Ernexa Therapeutics Inc

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest ERNA News

ERNAErnexa Therapeutics Inc